TME Pharma
TME Pharma is a clinical-stage company focusing on developing novel therapies for treatment of the most aggressive cancers. We specialize in approaches targeting the tumor microenvironment (TME) in which cancer cells exist. Our unique technology breaks tumor protection barriers against the immune system and blocks tumor repair by neutralizing chemokines in the TME. TME Pharma’s approach works in combination with other forms of treatment to weaken tumor defenses and enable greater therapeutic impact. Our clinical programs in glioblastoma and pancreatic cancer have delivered very promising results and further development is planned.
Updated corporate presentation with ESMO 15 Sept 2024 Oral Presentation data showing statistically significant improvement in survival |
Press Release2025, January 29 08:00 a.m. TME Pharma announces collaboration with aimed analytics for AI-driven drug discovery and optimization 2025, January 20 06:00 p.m. Half-yearly report on the liquidity contract with Invest Securities 2024, December 23 08:00 a.m. TME Pharma announces successful completion of Euro 2.6 million public offer with strong shareholder support |
EventsAllinvest Securities Biomed Forum
Aram Mangasarian, Ewelina Staniuk Latest Analyst ReportInvest Securities |